Colorectal Neoplasms Clinical Trials in Toronto, Ontario
7 recruitingToronto, Ontario, Canada
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 3
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Colorectal NeoplasmsNeoplasms by SiteGastrointestinal Neoplasms+7 more
Pfizer800 enrolled228 locationsNCT07222800
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled381 locationsNCT05253651
Recruiting
Phase 1
First in Human Study of AZD9592 in Solid Tumors
Carcinoma, Non-Small Cell LungColorectal NeoplasmsHead and Neck Neoplasms+1 more
AstraZeneca403 enrolled51 locationsNCT05647122
Recruiting
Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host
Breast CancerBreast NeoplasmsColorectal, Cancer+3 more
University Health Network, Toronto120 enrolled1 locationNCT02732860
Recruiting
Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Carcinoma, Non-Small Cell LungGastroesophageal Junction AdenocarcinomaStomach Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer914 enrolled44 locationsNCT06131840
Recruiting
Phase 1Phase 2
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Carcinoma, Non-Small Cell LungOvarian NeoplasmsColorectal Neoplasms+3 more
Eli Lilly and Company540 enrolled49 locationsNCT04956640